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FAMILY PLANNING

EVIDENCE

BRIEF

Family Planning Financing
Ensuring Adequate Financing of Family
Planning Commodities and Services
Increasing efficient and effective investment in family planning through
the public and private sectors is key to meeting the FP2020 goal of
helping 120 million additional women become modern contraceptive
users. Despite efforts by country governments, donors and individuals
are responsible for nearly half (49%) of the costs of reproductive,
maternal, neonatal, and children’s health (1). Household expenditures
dwarf the contributions of both domestic and international funding
sources. Future efforts to reduce unmet need for FP must consider
consumers’ out-of-pocket costs, programmatic cost-effectiveness, and
sources of funding.

CHALLENGES TO FINANCING
FAMILY PLANNING
The estimated direct and indirect annual cost of providing modern
contraceptive services to 671 million users in developing regions is
US$6.3 billion (2). Direct costs include contraceptives, supplies, and
health worker salaries. Indirect costs include programme support,
information and education on FP, construction and maintenance of
facilities, and supply chain management. This results in a total average
(including direct and indirect) cost for modern contraception per person
per year in developing regions of US$1.01.
Expanding and improving services to meet the needs of all women
and girls in developing regions (an additional 214 million) for modern
contraception would cost US$12 billion annually (including direct and
indirect) or US$1.93 per person per year (2).
The average cost per person in developing regions for modern contraceptive services and maternal and newborn care is US$8.56 or US$53.6
billion annually (2). Investing in both contraceptive and maternal and
newborn services together results in a net savings of $6.9 billion compared with investing in maternal and newborn health care alone.
If current trends in increased contraceptive use in 148 developing
countries and territories continue, there will be a funding gap of US$322
million in 2020 for commodities alone (2). If the FP2020 goal were fully
achieved, the remaining funding gap between amounts spent on supplies
in 2014 and 2020 would be US$541 million (3).
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POLICY AND PROGRAMME
CONSIDERATIONS
Ensure sustained fundraising,
pooling, and strategic
purchasing in order to scale
up delivery systems for
contraceptive methods.
Increase the number of
additional family planning users
by reaching new users and
improving continuation rates
among current users.
Conduct further research
on family planning quality
performance metrics, such
as the method information
index, to test their correlation
with higher continuation
rates. Client dissatisfaction
and discontinuation represent
significant risks to the success
of FP2020.

Resources from donors have increased over time, with the
US historically being the largest bilateral donor followed by
the UK (3). In 2015, the US contributed nearly half (47%) of
the bilateral funding for FP, contributing US$638 million,
and the UK contributed US$269.9 million (20%) (4).

CONSIDERATIONS FOR ENSURING
ADEQUATE FINANCING OF
FAMILY PLANNING COMMODITIES
AND SERVICES

There are also multilateral sources of funding, with the
UNFPA spending about 43% of its funds or US$341 million
on FP in 2015 and the World Bank spending US$251 million
on population and reproductive health. (4). Following the
creation of the Global Financing Facility (GFF), the World
Bank is expected to have a greater role in FP (4).

Increasing the number of additional FP users is
achieved both by reaching new users and by improving
continuation rates among current users (5,6). Further
research on FP quality performance metrics, such
as the method information index, is needed to test
their correlation with improved continuation rates.
Particularly as contraceptive prevalence increases, client
dissatisfaction and discontinuation represent a significant
risk to the success of the FP2020 initiative (7).

Foundations and the private sector have also made sizeable
contributions to reproductive health, with the Bill & Melinda
Gates Foundation, for example, spending US$148 million for
family planning in 2015 (4). And pharmaceutical companies
have played a role in partnership with donors through
innovative financing mechanisms that have seen significant
reductions in the price of contraceptives – most notably by
Bayer and Merck for contraceptive implants.
However, the outlook for future donor funding is uncertain
given the instability in currency exchange rates, changing
donor-country political agendas, creation of the GFF, and
other global developments. The 2018 US budget withheld
contribution to UNFPA and level funded family planning,
however significant reductions are planned in 2017 (4).
Moreover, domestic funding commitments are highly
variable between countries. Domestic financing will likely
require more engagement of ministries of finance as well
as ministries of health to emphasize the demographic
dividend. The demographic dividend is an increase
in economic growth and development that could be
achieved if changes in the population age structure
result in declining fertility rates as a result of increased
contraceptive use coupled with investments to improve
education, job creation, efficiency in revenue generation
and tax collection, and increased tax rates (1). Greater
integration of public and private sectors in service delivery,
pooling of procurement, and strategic purchasing will lead
to more efficient and higher per capita spending with more
consistent investment. Serving women and hard-to-reach
populations in low-income countries requires an integrated
approach to strengthening health systems in order to move
toward universal health coverage (1).
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Achieving universal access to family planning would
have one of the highest benefit-cost ratios among a
wide choice of policy options for development (8).
Social and economic benefits for women, their families,
and societies will result from increases in women’s and
children’s education, increases in women’s earnings, and
further reductions in poverty (2). In health, prevention
is much cheaper than treatment; the cost of modern
contraception is much lower than providing care for
unintended pregnancies. For each additional dollar spent
on FP above the current level, the cost of pregnancyrelated care in developing regions is reduced by US$2.20
(2). If needs for modern contraception and maternal
and newborn care were fully met, the result would be a
net savings of US$6.9 billion compared with investing in
maternal and newborn health care alone (2). Investing
in modern contraception will provide a great return on
investment that compounds over time (12).
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